U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H14NO6.Na
Molecular Weight 375.3073
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACENOCOUMAROL SODIUM, (S)-

SMILES

[Na+].CC(=O)C[C@@H](C1=CC=C(C=C1)[N+]([O-])=O)C2=C([O-])C3=C(OC2=O)C=CC=C3

InChI

InChIKey=MPRDFQJZNXOBJT-RSAXXLAASA-M
InChI=1S/C19H15NO6.Na/c1-11(21)10-15(12-6-8-13(9-7-12)20(24)25)17-18(22)14-4-2-3-5-16(14)26-19(17)23;/h2-9,15,22H,10H2,1H3;/q;+1/p-1/t15-;/m0./s1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C19H14NO6
Molecular Weight 352.3176
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: The description was created based on several sources, including http://file.scirp.org/Html/4-2201103_53725.htm | https://www.ncbi.nlm.nih.gov/pubmed/2865109

(S)-Acenocoumarol is a short-lived oral anti-coagulant, which, like warfarin, functions by inhibiting vitamin K epoxide reductase. (S)-Acenocoumarol has a shorter plasma elimination half-life (1.8 hours) and faster plasma clearance (28.5 L/hour), compared to the (R)-enantiomer (6.6 hours, 1.9 L/hour). The S-enantiomer undergoes extensive first-pass metabolism during absorption from the gastrointestinal tract, whereas (R)-acenocoumarol is rapidly absorbed and provides essentially complete oral bioavailability. Perhaps related to these pharmacokinetic characteristics, (S)-acenocoumarol is less potent in vivo as an anti-coagulant than the (R)-enantiomer. As the clearance of acenocoumarol is ~20-fold faster than that of warfarin, the plasma concentrations of acenocoumarol are substantially lower than those for warfarin in patients receiving long-term treatment.

Originator

Sources: British Journal of Clinical Pharmacology (1978), 5, (2), 187-8.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SINTROM

Approved Use

Unknown
Primary
SINTROM

Approved Use

Unknown
Primary
SINTROM

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Stereoselective aspects in the pharmacokinetics and pharmacodynamics of acenocoumarol and its amino and acetamido derivatives in the rat.
1985-09-01
Patents

Patents

Sample Use Guides

Rats were treated with (S)-Acenocoumarol 1mg as a single dose
Route of Administration: Oral
Acenocoumarol had no effect in unstimulated cells but in PHA-stimulated PBMC tryptophan breakdown and the formation of neopterin, as well as IFN-γ and TNF-α, were dose-dependently suppressed at concentrations as low as 10 μg/ml. Likewise, acenocoumarol dose-dependently inhibited tryptophan breakdown in IFN-γ stimulated Caco-2 cells. Interestingly, NF-κB expression was super-induced in the LPS treated cells.
Substance Class Chemical
Created
by admin
on Mon Mar 31 22:30:35 GMT 2025
Edited
by admin
on Mon Mar 31 22:30:35 GMT 2025
Record UNII
R159V074GS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACENOCOUMAROL SODIUM, (S)-
Common Name English
(S)-ACENOCOUMAROL SODIUM SALT
Preferred Name English
Code System Code Type Description
FDA UNII
R159V074GS
Created by admin on Mon Mar 31 22:30:35 GMT 2025 , Edited by admin on Mon Mar 31 22:30:35 GMT 2025
PRIMARY
PUBCHEM
91799741
Created by admin on Mon Mar 31 22:30:35 GMT 2025 , Edited by admin on Mon Mar 31 22:30:35 GMT 2025
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
RACEMATE -> ENANTIOMER